Saturday, July 11, 2026
🇺🇸 FDA

Patent directory · USPTO A61K / A61P

Patents matching “treatment”

2,520 pharma patents match "treatment" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 2,520
Index total 30,257
Page 38 / 105

Quick answer

This filtered view shows 2,520 pharmaceutical patents matching "treatment" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

2,520 results for “treatment” · 30,257 patents in full index Clear search

  1. US 10857174

    Morpholino oligonucleotides useful in cancer treatment

    United States Government as represented by the Department of Veterans Affairs · Granted Dec 8, 2020 · Expires Dec 3, 2040

    granted

  2. US 10849912

    Method of sensitizing cancer cells to the cytotoxic effects of apoptosis inducing ligands in cancer treatment

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Dec 1, 2020 · Expires Nov 26, 2040

    granted

  3. US 10849936

    Compositions and methods for C. difficile treatment

    Regents of the University of Minnesota · Granted Dec 1, 2020 · Expires Nov 26, 2040

    granted

  4. US 10844052

    LLS compounds for treatment of cancer

    The Regents of the University of California · Granted Nov 24, 2020 · Expires Nov 19, 2040

    granted

  5. US 10842835

    Oncolytic vaccinia virus mutants and using same for cancer treatment

    ARIZONA BOARD OF REGENTS FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY · Granted Nov 24, 2020 · Expires Nov 19, 2040

    granted

  6. US 10842823

    Treatment of pulmonary arterial hypertension with prostacyclin-treated endothelial progenitor cells

    United Therapeutics Corporation · Granted Nov 24, 2020 · Expires Nov 19, 2040

    granted

  7. US 10835755

    Method of using laser-induced optoacoustics for the treatment of drug-resistant microbial infections

    United States of America as represented by the Secretary of the Air Force · Granted Nov 17, 2020 · Expires Nov 12, 2040

    granted

  8. US 10835513

    Methods and treatments for the learning and memory deficits associated with Noonan syndrome

    The Regents of the University of California · Granted Nov 17, 2020 · Expires Nov 12, 2040

    granted

  9. US 2020345623

    METHODS OF SCAR PREVENTION AND/OR TREATMENT

    ALLERGAN PHARMACEUTICALS INT LTD [IE] · Granted Nov 5, 2020 · Expires Oct 31, 2040

    granted

  10. US 10822427

    Anti-CSPG4 fusions with interferon for the treatment of malignancy

    The Regents of the University of California · Granted Nov 3, 2020 · Expires Oct 29, 2040

    granted

  11. US 10813917

    Treatment methods utilizing stem cell mobilizers and immunosuppressive agents

    MedRegen, LLC · Granted Oct 27, 2020 · Expires Oct 22, 2040

    granted

  12. US 10815285

    Recombinant adeno-associated virus-mediated expression of fractalkine for treatment of neuroinflammatory and neurodegenerative diseases

    United States Government as represented by the Department of Veterans Affairs · Granted Oct 27, 2020 · Expires Oct 22, 2040

    granted

  13. US 10813899

    Use of (s)-3-amino-4-(difluoromethylenyl) cyclopent-1-ene-l-carboxylic acid and related compounds, (1s,3S)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and vigabatrin in the treatment of developmental disorders

    OVID THERAPEUTICS INC. · Granted Oct 27, 2020 · Expires Oct 22, 2040

    granted

  14. US 10815266

    β-D-2′-deoxy-2′-α-fluoro-2′-β-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment

    Atea Pharmaceuticals, Inc. · Granted Oct 27, 2020 · Expires Oct 22, 2040

    granted

  15. US 10813909

    Triple drug combination (metformin, simvastatin, digoxin) for targeted treatment of pancreatic cancer

    The Regents of the University of California · Granted Oct 27, 2020 · Expires Oct 22, 2040

    granted

  16. US 10813918

    Use of Gaboxadol in the treatment of diabetes and related conditions

    OVID THERAPEUTICS INC. · Granted Oct 27, 2020 · Expires Oct 22, 2040

    granted

  17. US 10799525

    Composition of novel carbohydrate drug for treatment of human diseases

    GALECTIN THERAPEUTICS, INC. · Granted Oct 13, 2020 · Expires Oct 8, 2040

    granted

  18. US 10799485

    Methods and compositions for treatment of epileptic disorders

    OVID THERAPEUTICS INC. · Granted Oct 13, 2020 · Expires Oct 8, 2040

    granted

  19. US 10799512

    Estrogen combination for treatment of multiple sclerosis

    The Regents of the University of California · Granted Oct 13, 2020 · Expires Oct 8, 2040

    granted

  20. US 10799514

    Non-hormonal steroid modulators of NF-kappa beta for treatment of disease

    ReveraGen BioPharma, Inc. · Granted Oct 13, 2020 · Expires Oct 8, 2040

    granted

  21. US 10799713

    Miniature wearable laser treatment device

    Veralase, LLC · Granted Oct 13, 2020 · Expires Oct 8, 2040

    granted

  22. US 10799559

    NOPE for treatment of pathological muscle loss and weakness

    Five Prime Therapeutics, Inc. · Granted Oct 13, 2020 · Expires Oct 8, 2040

    granted

  23. US 2020318108

    MATERIALS AND METHODS FOR TREATMENT OF USHER SYNDROME TYPE 2A AND/OR NON-SYNDROMIC AUTOSOMAL RECESSIVE RETINITIS PIGMENTOSA (ARRP)

    CRISPR THERAPEUTICS AG [CH] · Granted Oct 8, 2020 · Expires Oct 3, 2040

    granted

  24. US 10793547

    Modulator of the cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator

    Vertex Pharmaceuticals Incorporated · Granted Oct 6, 2020 · Expires Oct 1, 2040

    granted

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.